QCC374X
Total Payments
$55,318
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $53,483 | 4 | 0 |
| 2017 | $1,835 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,318 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED PARALLEL GROUP PLACEBO CONTROLLED SUBJECT AND INVESTIGATOR BLINDED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF QCC374 IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Novartis Pharmaceuticals Corporation | $55,318 | 0 |
Top Doctors Receiving Payments for QCC374X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Milwaukee, WI | $55,318 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $55,318
- Total Doctors 0
- Transactions 7
About QCC374X
QCC374X is a drug associated with $55,318 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $53,483 was paid across 4 transactions to 0 doctors.
The most common payment nature for QCC374X is "Unspecified" ($55,318, 100.0% of total).
QCC374X is associated with 1 research study, including "A RANDOMIZED PARALLEL GROUP PLACEBO CONTROLLED SUBJECT AND INVESTIGATOR BLINDED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF QCC374 IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION" ($55,318).